Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
Company plans to request re-examination following negative CHMP opinion for arimoclomol MAA
Covered in this story
What has happened since
- Mid-America Apartment Communities is down 12.3% since this was published, 88 days ago.
- Zevra Therapeutics Inc is up 9.9% since this was published, 88 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $MAA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Mid-America Apartment Communities →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.